Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02280603
Recruitment Status : Completed
First Posted : October 31, 2014
Last Update Posted : June 24, 2015
Sponsor:
Information provided by (Responsible Party):
Dong-A ST Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This study is designed to explore the efficacy and safety of DA-4001 after topical application in male patients with androgenetic alopecia

Design : Randomized, double-blind, active-controlled study

Investigational Product : Finasteride, minoxidil


Condition or disease Intervention/treatment Phase
Androgenetic Alopecia Drug: DA-4001C Drug: 5% minoxidil Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia
Study Start Date : January 2014
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Minoxidil

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: DA-4001C
DA-4001C is administered
 Drug: DA-4001C
1ml by topical application twice a day
Active Comparator: 5% minoxidil
5% minoxidil is administered
 Drug: 5% minoxidil
1ml by topical application twice a day
Other Name: minoxyl


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change from baseline in target area hair count per cm2 at week 24, as assessed by phototrichogram [ Time Frame: baseline and week 24 ]

Secondary Outcome Measures :
  1. Change from baseline in target area hair count per cm2 at week 16, as assessed by phototrichogram [ Time Frame: Baseline and week 16 ]
  2. Improvement rate of target area hair count per cm2 at week 16 and week 24, as assessed by phototrichogram [ Time Frame: Baseline, week 16,and week24 ]
  3. Improvement rate of target area mean hair diameter at week 16 and week 24, as assessed by phototrichogram [ Time Frame: Baseline, week 16, and week 24 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Basic and specific(BASP) classification : basic type is M2 or C2 and specific type is V1,V2 or F1,F2

Exclusion Criteria:

  • Evidence of hair loss other than androgenetic alopecia
  • Use of finasteride, dutasteride within previous 12 months
  • Use of minoxidil within previous 6 months
  • Use of androgenic or anti-androgenic agents within previous 6 months
  • Use of steroid agents for local application to scalp or systemic application within previous 1 month
  • History of hair transplantation, scalp reduction
  • Coronary artery disease, arrhythmia, congestive heart failure, valvular haert disease, angina pectoris
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02280603


Locations
Layout table for location information
Korea, Republic of
Catholic Medical Center
Seoul, Dongdaemun-gu, Korea, Republic of, 130-709
Sponsors and Collaborators
Dong-A ST Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Hoon Kang, M.D, Ph.D The catholic univ. of korea, St.Paul's hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Dong-A ST Co., Ltd.
ClinicalTrials.gov Identifier: NCT02280603    
Other Study ID Numbers: DA4001_AGAP_POC
First Posted: October 31, 2014    Key Record Dates
Last Update Posted: June 24, 2015
Last Verified: June 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia
Alopecia Areata
Hypotrichosis
Hair Diseases
Skin Diseases
 Pathological Conditions, Anatomical
Minoxidil
Antihypertensive Agents
Vasodilator Agents